PMID- 10680037
OWN - NLM
STAT- MEDLINE
DCOM- 20000316
LR  - 20240402
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 23 Suppl 1
IP  - Suppl
DP  - 2000 Jan
TI  - Can we differentiate the low-molecular-weight heparins?
PG  - I4-7
AB  - The low-molecular-weight heparins (LMWHs) have a number of therapeutic 
      advantages, relative to standard unfractionated heparin (UFH). They are readily 
      bioavailable when injected subcutaneously and can be given in fixed doses, 
      allowing for far simpler administration. Several LMWHs are now commercially 
      available, each demonstrating different physical and chemical properties and 
      different activities in animal models of anticoagulation or hemorrhage. In 
      clinical comparisons with placebo in the treatment of unstable coronary artery 
      disease (UCAD), the LMWHs dalteparin sodium and nadroparin calcium have 
      demonstrated good anticoagulant efficacy. In comparisons with UFH, on the other 
      hand, only enoxaparin has shown superior anticoagulant activity, as reported in 
      the results of the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave 
      Coronary Events (ESSENCE) and Thrombolysis In Myocardial Infarction (TIMI) 11B 
      trials. However, close scrutiny of the methodology of the clinical trials in UCAD 
      reveals considerable differences in study designs, dosage regimens, duration of 
      administration of active treatments, and the timing and definition of endpoints. 
      Therefore, it would not be scientifically sound to compare results with the 
      different LMWHs based on the current available studies. It is also not possible 
      to draw any conclusions with regard to the relative efficacy of the different 
      LMWHs, since there are no properly-sized comparative data between dalteparin 
      sodium, enoxaparin sodium, and nadroparin calcium.
FAU - Turpie, A G
AU  - Turpie AG
AD  - Department of Medicine, Hamilton Health Sciences Corporation, Ontario, Canada. 
      turpiea@fhs.mcmaster.ca
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Nadroparin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Anticoagulants/*pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Coronary Thrombosis/*drug therapy/prevention & control
MH  - Dalteparin/pharmacology/therapeutic use
MH  - Drug Administration Schedule
MH  - Enoxaparin/pharmacology/therapeutic use
MH  - Heparin, Low-Molecular-Weight/chemistry/*pharmacology/*therapeutic use
MH  - Humans
MH  - Nadroparin/pharmacology/therapeutic use
MH  - Research Design
PMC - PMC6655236
EDAT- 2000/02/19 09:00
MHDA- 2000/03/18 09:00
PMCR- 2009/02/03
CRDT- 2000/02/19 09:00
PHST- 2000/02/19 09:00 [pubmed]
PHST- 2000/03/18 09:00 [medline]
PHST- 2000/02/19 09:00 [entrez]
PHST- 2009/02/03 00:00 [pmc-release]
AID - CLC4960231303 [pii]
AID - 10.1002/clc.4960231303 [doi]
PST - ppublish
SO  - Clin Cardiol. 2000 Jan;23 Suppl 1(Suppl ):I4-7. doi: 10.1002/clc.4960231303.